Raya Leibowitz‐Amit

Author

Raya Leibowitz‐Amit

Also Known As

Paul Donnellan, R Leibowitz, R Leibowitz-Amit, R. L. Leibowitz, R. Leibowitz, R. Leibowitz-Amit, R. Leibowitz–Amit, Raya Leibowitz, Raya Leibowitz-Amit, Raya Leibowitz-amit

141

Publications

8.7K

Citations

H-Index

Concepts

All Affiliations

Sheba Medical Center Tel Aviv University Princess Margaret Cancer Centre BC Cancer Agency Rambam Health Care Campus

About

Raya Leibowitz‐Amit is an author at Sheba Medical Center specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	18	3K
2	Cell Biology	3	3	143
3	Public Health	1	1	102
4	Social Sciences	1	1	368
5	Emergency Medicine	1	1	102

Raya Leibowitz‐Amit

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy Gila Moalem‐Taylor, Raya Leibowitz‐Amit, Eti Yoles, Nature Medicine Secondary DegenerationAutoimmune DiseaseMedicineImmunologyAutoimmunity	1999	886
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial Robert J. Motzer, Brian I. Rini, David F. McDermott, The Lancet Oncology UrologyGenitourinary CancerMedicinePharmacologyImmune Checkpoint Inhibitor	2019	763
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019 Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, European Urology	2020	384
Passive or Active Immunization with Myelin Basic Protein Promotes Recovery from Spinal Cord Contusion Ehud Hauben, Oleg Butovsky, Uri Nevo, Journal of Neuroscience ImmunologyPartial InjuryNeurological InjuryT CellsSpinal Disorder	2000	368
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial Robert J. Motzer, Bernard Escudier, David F. McDermott, Journal for ImmunoTherapy of Cancer	2020	222
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial Daniel P. Petrylak, Ronald de Wit, Kim N., The Lancet Platinum-based TherapyUrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicine	2017	175
Simple prognostic score for metastatic castration‐resistant prostate cancer with incorporation of neutrophil‐to‐lymphocyte ratio Arnoud J. Templeton, Carmel Pezaro, Aurelius Omlin, Cancer	2014	140
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials Arnoud J. Templeton, Francisco Vera-Badillo, L. Wang, Annals of Oncology UrologyOncologyClinical TrialsOutcomes ResearchRandomized Controlled Trial	2013	136
Silencing of a large microRNA cluster on human chromosome 14q32 in melanoma: biological effects of mir-376a and mir-376c on insulin growth factor 1 receptor Liron Zehavi, Roi Avraham, Aviv Barzilai, Molecular Cancer	2012	135
A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial Grainne M. O’Kane, Shereen Ezzat, Anthony M. Joshua, British Journal of Cancer	2019	119

Page 1